Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy.

ABSTRACT: Although the discovery of immune checkpoints was hailed as a major breakthrough in cancer therapy, generating a sufficient response to immunotherapy is still limited. Thus, the objective of this exploratory, hypothesis-generating study was to identify potentially novel peripheral biomarkers and discuss the possible predictive relevance of combining scarcely investigated metabolic and hormonal markers with immune subsets. Sixteen markers that differed significantly between responders and non-responders were identified. In a further step, the correlation with progression-free survival (PFS) and false discovery correction (Benjamini and Hochberg) revealed potential predictive roles for the immune subset absolute lymphocyte count (rs = 0.51; p = 0.0224 *), absolute basophil count (rs =

SUBMITTER: Hofbauer J 

PROVIDER: S-EPMC9139165 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature